D-1294-2019 Class II Terminated

Recalled by MALLINCKRODT PHARMACEUTICALS — Bedminster, NJ

FDA drug recall D-1294-2019 was initiated by MALLINCKRODT PHARMACEUTICALS on May 13, 2019 and is designated Class II. Reason for recall: Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct… The recall status is terminated (terminated Jul 17, 2023). Affected quantity: 89,808 bottles.

Recall details

Product Type
Drugs
Report Date
May 29, 2019
Initiation Date
May 13, 2019
Termination Date
Jul 17, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
89,808 bottles

Product description

Amitiza (lubiprostone) capsules, 8 mcg, 60-count bottle, Rx only, Manufactured by: Sucampo Pharma Americas, LLC, NDC 64764-080-60

Reason for recall

Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue.

Distribution pattern

US Nationwide

Code information

Lot #: 3229691-61, Exp 01/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1294-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1294-2019. Report a data issue: hello@regdatalab.com.